Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$41.01 USD
+0.64 (1.59%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $41.02 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
XENE 41.01 +0.64(1.59%)
Will XENE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XENE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XENE
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
XENE: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
Other News for XENE
Xenon Pharmaceuticals: Q2 Earnings Snapshot
Xenon Reports Q2 2024 Financial Results and Business Update
Robust Financials and Promising Clinical Trials Bolster Xenon Pharma’s Buy Rating
XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024
TD Cowen Keeps Their Buy Rating on Xenon (XENE)